DEUTSCHE BANK AG\ - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 108 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$93,330
+504.7%
79,094
+622.5%
0.00%
Q2 2023$15,435
-85.3%
10,947
-83.9%
0.00%
Q1 2022$105,000
-43.9%
68,085
-10.6%
0.00%
Q4 2021$187,000
+2.7%
76,161
+5.6%
0.00%
Q3 2021$182,000
-11.2%
72,135
+0.2%
0.00%
Q2 2021$205,000
+632.1%
71,992
+113.8%
0.00%
Q1 2020$28,000
-9.7%
33,680
-6.1%
0.00%
Q4 2019$31,000
+14.8%
35,868
+26.0%
0.00%
Q3 2019$27,00028,4660.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2019
NameSharesValueWeighting ↓
Defender Capital, LLC. 5,036,720$14,354,0004.77%
BROADWOOD CAPITAL INC 34,005,379$96,915,0004.33%
Prescott General Partners LLC 1,851,851$5,278,0000.17%
Raffles Associates 43,590$124,0000.10%
Laidlaw Wealth Management LLC 123,730$353,0000.09%
DCF Advisers, LLC 74,500$212,0000.08%
Beirne Wealth Consulting Services, LLC 45,000$128,0000.07%
Strategic Wealth Investment Group, LLC 64,232$183,0000.06%
Paradigm, Strategies in Wealth Management, LLC 19,775$56,0000.05%
Fort Sheridan Advisors LLC 47,931$137,0000.05%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders